Literature DB >> 31578227

Genetic and Epigenetic Characterization of Growth Hormone-Secreting Pituitary Tumors.

Niko Välimäki1,2, Camilla Schalin-Jäntti3, Atte Karppinen4, Anders Paetau5, Leena Kivipelto4, Lauri A Aaltonen1,2, Auli Karhu6,2.   

Abstract

Somatic driver mechanisms of pituitary adenoma pathogenesis have remained incompletely characterized; apart from mutations in the stimulatory Gα protein (Gαs encoded by GNAS) causing activated cAMP synthesis, pathogenic variants are rarely found in growth hormone-secreting pituitary tumors (somatotropinomas). The purpose of the current work was to clarify how genetic and epigenetic alterations contribute to the development of somatotropinomas by conducting an integrated copy number alteration, whole-genome and bisulfite sequencing, and transcriptome analysis of 21 tumors. Somatic mutation burden was low, but somatotropinomas formed two subtypes associated with distinct aneuploidy rates and unique transcription profiles. Tumors with recurrent chromosome aneuploidy (CA) were GNAS mutation negative (Gsp- ). The chromosome stable (CS) -group contained Gsp+ somatotropinomas and two totally aneuploidy-free Gsp- tumors. Genes related to the mitotic G1-S-checkpoint transition were differentially expressed in CA- and CS-tumors, indicating difference in mitotic progression. Also, pituitary tumor transforming gene 1 (PTTG1), a regulator of sister chromatid segregation, showed abundant expression in CA-tumors. Moreover, somatotropinomas displayed distinct Gsp genotype-specific methylation profiles and expression quantitative methylation (eQTM) analysis revealed that inhibitory Gα (Gαi) signaling is activated in Gsp+ tumors. These findings suggest that aneuploidy through modulated driver pathways may be a causative mechanism for tumorigenesis in Gsp- somatotropinomas, whereas Gsp+ tumors with constitutively activated cAMP synthesis seem to be characterized by DNA methylation activated Gαi signaling. IMPLICATIONS: These findings provide valuable new information about subtype-specific pituitary tumorigenesis and may help to elucidate the mechanisms of aneuploidy also in other tumor types. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31578227     DOI: 10.1158/1541-7786.MCR-19-0434

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  6 in total

1.  Potential markers of disease behavior in acromegaly and gigantism.

Authors:  Laura C Hernández-Ramírez
Journal:  Expert Rev Endocrinol Metab       Date:  2020-05-06

2.  Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors.

Authors:  Agnese Re; Francesco Ferraù; Concetta Cafiero; Federica Spagnolo; Valeria Barresi; Daniela Petronilla Romeo; Marta Ragonese; Claudio Grassi; Alfredo Pontecorvi; Antonella Farsetti; Salvatore Cannavò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-12       Impact factor: 5.555

3.  Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.

Authors:  Hélène Lasolle; Mad-Hélénie Elsensohn; Anne Wierinckx; Eudeline Alix; Clément Bonnefille; Alexandre Vasiljevic; Christine Cortet; Bénédicte Decoudier; Nathalie Sturm; Stephan Gaillard; Amandine Ferrière; Pascal Roy; Emmanuel Jouanneau; Philippe Bertolino; Claire Bardel; Damien Sanlaville; Gérald Raverot
Journal:  Acta Neuropathol Commun       Date:  2020-11-10       Impact factor: 7.801

Review 4.  Genetic and Epigenetic Causes of Pituitary Adenomas.

Authors:  Mengqi Chang; Chengxian Yang; Xinjie Bao; Renzhi Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-26       Impact factor: 5.555

Review 5.  Genetic and Epigenetic Pathogenesis of Acromegaly.

Authors:  Masaaki Yamamoto; Yutaka Takahashi
Journal:  Cancers (Basel)       Date:  2022-08-10       Impact factor: 6.575

Review 6.  Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.

Authors:  Vinaya Srirangam Nadhamuni; Márta Korbonits
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.